Statistics from Altmetric.com
We read with interest the article by Hikichi et al 1 describing the 2-year outcomes of intravitreal ranibizumab monotherapy for the treatment of patients with polypoidal choroidal vasculopathy (PCV). The authors reported significant improvement in visual acuity compared with baseline for both the first and second years, and a corresponding decrease in the mean foveal thickness measured on optical coherence tomography.
While these results are indeed encouraging, we feel that it is important to discuss the frequency of polyp regression and its implications on the long-term prognosis of patients with PCV. In the current study, the proportion of eyes in which no polypoidal lesions were detected on indocyanine green angiography was 40% 1 year after the first injection and …